Clinical utility of anti‐cytosolic 5’‐nucleotidase 1A antibody in idiopathic inflammatory myopathies
Authors:
Open Access
- 8 February 2021
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 8 (3) , 571-578
Abstract
Objective: To define the clinicopathologic features and diagnostic utility associated with anti‐cytosolic 5′‐nucleotidase 1A (NT5C1A) antibody seropositivity in idiopathic inflammatory myopathies (IIMs).Methods: Anti‐NT5C1A antibody status was clinically tested between 2014 and 2019 in the Washington University neuromuscular clinical laboratory. Using clinicopathologic information available for 593 patients, we classified them as inclusion body myositis (IBM), dermatomyositis, antisynthetase syndrome, immune‐mediated necrotizing myopathy (IMNM), nonspecific myositis, or noninflammatory muscle diseases.Results: Of 593 patients, anti‐NT5C1A antibody was found in 159/249 (64%) IBM, 11/53 (21%) dermatomyositis, 7/27 (26%) antisynthetase syndrome, 9/76 (12%) IMNM, 20/84 (24%) nonspecific myositis, and 6/104 (6%) noninflammatory muscle diseases patients. Among patients with IBM, anti‐NT5C1A antibody seropositive patients had more cytochrome oxidase‐negative fibers compared with anti‐NT5C1A antibody seronegative patients. Among 14 IBM patients initially negative for anti‐NT5C1A antibody, three patients (21%) converted to positive. Anti‐NT5C1A antibody seropositivity did not correlate with malignancy, interstitial lung disease, response to treatments in dermatomyositis, antisynthetase syndrome, and IMNM, or survival in IIMs.Interpretation: Anti‐NT5C1A antibody is associated with IBM. However, the seropositivity can also be seen in non‐IBM IIMs and it does not correlate with any prognostic factors or survival.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Targeted sequencing and identification of genetic variants in sporadic inclusion body myositisNeuromuscular Disorders, 2015
- Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-upRheumatology International, 2014
- Cytoplasmic 5′‐nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utilityMuscle & Nerve, 2014
- 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The NetherlandsNeuromuscular Disorders, 2013
- Cytosolic 5′‐nucleotidase 1A autoimmunity in sporadic inclusion body myositisAnnals of Neurology, 2012
- Autoantibodies to cytosolic 5′‐nucleotidase 1A in inclusion body myositisAnnals of Neurology, 2012
- Interstitial Lung Disease Associated With the Idiopathic Inflammatory MyopathiesChest, 2010
- Inflammatory myopathies with mitochondrial pathology and protein aggregatesJournal of the Neurological Sciences, 2009
- 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The NetherlandsNeuromuscular Disorders, 2004
- PolymyositisNeurology, 2003